Traditional Therapy Profiles ยท Ingredient

Amla

Also called: amalaki, Indian gooseberry, Emblica officinalis

Amla names the fruit. The formulation names the evidence.

New here? How to read these profiles

The important distinction

Amla extract trials study standalone amla. Patients meet the same fruit as a Triphala third, a Nishamalaki half, a chyawanprash base, and an antioxidant juice. Solo literature does not prove every product that lists amalaki.

What it is

Amla is the fruit of Emblica officinalis (also classified as Phyllanthus emblica), called amalaki in classical Ayurvedic texts and Indian gooseberry in English.

Amla is one fruit name with several formulation homes. Its reputation grew because it sits inside so many classical products. That ubiquity is larger than the solo extract literature.

Where you will encounter it

  • One-third of Triphala alongside haritaki and bibhitaki
  • Half of Nishamalaki paired with turmeric for metabolic use
  • The usual anchor fruit in chyawanprash-type jams and rasayana products
  • Standalone amla capsules, powders, and "Indian gooseberry" antioxidant juices
  • Practitioner prescriptions where amalaki appears inside larger compound formulas

Further detail

Formulation homes

Solo extract evidence does not travel to every product that lists amalaki.

Standalone capsules and powders are one home. Triphala is another: amla is one of three fruits, and the combination is the medicine. Nishamalaki is a named turmeric-and-amla pair. Chyawanprash-type jams use amla as an anchor fruit among many herbs. Antioxidant juice is a beverage matrix, not an extract protocol. Same fruit name. Different evidence objects.

What human research has studied

Evidence attaches to the formulation home, not to the fruit name alone.

A 2023 systematic review and meta-analysis of randomized trials reports that standalone amla supplementation improves fasting glucose, HbA1c, lipids, and C-reactive protein compared with control. Effect sizes are modest, study quality varies, and doses and extract forms differ.

Separate trial work exists on branded chyawanprash products and on the Nishamalaki pair. Triphala combination trials are another lane again. Formula marketing often inherits more from the fruit's reputation than any one home's trials deliver.

What the evidence does not justify
  • Using solo amla meta-analyses to prove every Triphala, Nishamalaki, or chyawanprash product on the shelf
  • Treating antioxidant juice marketing as equivalent to extract trials with stated doses
  • Assuming "vitamin C fruit" folk logic covers glucose or lipid claims at supplement doses
  • Replacing prescribed diabetes or lipid therapy because a formula lists amalaki
  • Collapsing practitioner compound prescriptions into one ingredient's retail evidence
Questions worth asking

The useful first question is "Which formulation home?"

  • Standalone amla or one line inside a named formula?
  • Extract, powder, juice, or jam spoonful?
  • Which claim is on the table: immunity, metabolism, or digestion?
  • Other glucose-lowering agents or antiplatelet medicines in use?
Safety and interaction attention

Safety follows the product in hand, not the fruit name alone.

Food and moderate supplemental use is common in trials. Hypoglycemia stacking with diabetes medicines is plausible when extracts are used alongside pharmacotherapy. Antiplatelet interaction literature exists at higher supplemental doses and deserves explicit review.

Related entries

Amla is one fruit name. Each formulation home is a separate evidence conversation.

  1. Triphala Formulation Amla is the third fruit. Solo amla trials do not prove the three-fruit blend patients buy.
  2. Nishamalaki Formulation Classical turmeric-and-amla pair. Metabolic literature on amla alone is not the same claim.
  3. Chyawanprash-type products Product pattern Often the anchor fruit in the jam. Brand trials on the jar do not equal standalone extract capsules.

Commonly confused with

  • Generic "Indian gooseberry" juice (beverage dose and matrix, not extract trial equivalence)
  • Any dark herbal jam labeled immunity (read ingredients; amalaki presence does not make products interchangeable)
  • Haritaki or bibhitaki (sibling Triphala fruits with their own ingredient lanes)
Sources
  1. Setayesh L, et al. The impact of Emblica officinalis (Amla) on lipid profile, glucose, and C-reactive protein: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Syndr. 2023. doi:10.1016/j.dsx.2023.102729
  2. Magavern EF, et al. Survey to inform personalised prescribing in a British South Asian community. BMC Med. 2026. doi:10.1186/s12916-026-04914-9

Evidence blocks last reviewed: July 2026.

← Back to Traditional Therapy Profiles